Video Interview: Ergomed Pursues Shared-Risk Approach To Help VC-Backed Biotechs
This article was originally published in Scrip
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies. CBO Andrew Mackie explains to Mike Ward, Informa's global director of content for pharma insights, how the company is prepared to share the risks and rewards of drug development, leveraging its expertise and services in return for carried interest in the drugs under development.
Register for our free email digests: